基于CiteSpace脑白质病的相关文献分析

摘要
图/表
参考文献(20)
相关文章 (14)

全文: PDF (1383 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的通过对脑白质病近15年来临床神经科学方面的文献进行可视化分析，探索脑白质病的主要研究方向及热点。方法运用顺查法检索Web of Science中的SCI-E中2004年1月～2018年12月脑白质病相关文献，应用CiteSpaceV 5.4.R3进行作者、研究机构、国家合作关系、关键词共现分析，对其文献、期刊共被引进行可视化分析。结果共获得3181篇，年平均发文量接近212篇。发文量总体呈上升趋势，2017年达到近15年来的引文最高峰。发文量最高的作者为van der Knaap MS。在该领域领先的国家是美国、德国、意大利，这些国家文献产量较多，且合作较为密切。梅奥诊所和慕尼黑大学是该领域的权威机构。热点的关键词为那他珠单抗、脑白质营养不良、脑白质病、皮层下梗死、消失的白质等，可形成8个聚类群。被引频次最高的期刊是Neurology。共被引频次最多的文献为Bloomgren G等发表的关于与那他珠单抗相关的进行性多造型脑白质病发病风险的文章。中心性排名最高的文献是Gorelik L等于2010年在Ann Neurol上发表的关于抗JC病毒抗体对脑白质病风险分层的影响的文章。结论应用CiteSpace对脑白质病近15年来临床神经科学方面的相关文献分析，展示出了目前合作的国家和机构，揭示了研究的热点及方向，对脑白质病的深入研究具有重要参考价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	韦妮娜徐曼曼潘菊华黄世敬▲ 王彦云

关键词 ：脑白质病, 文献计量学, 可视化分析, CiteSpace

Abstract：Objective To explore the main research directions and hot pots of leukoencephalopathy by visual analysis of clinical neuroscience literature in the past 15 years. Methods The literature related to leukoencephalopathy in SCI-E from January 2004 to December 2018 in Web of Science was searched with the method of cis search. CiteSpaceV 5.4.R3 was applied to analyze the authors, research institutions, national cooperation relations, keywords co-occurrence analysis, and to visually analyze the co-citation of their literature and journals. Results A total of 3181 papers were obtained, with an average annual volume of nearly 212 papers. The number of published articles on the whole showed an upward trend, reaching the highest citation level in the past 15 years in 2017. The author with the highest amount of published articles was van der Knaap MS. The leading countries in this field were the United States, Germany and Italy, which produced more literature and cooperate closely. The Mayo clinic and the university of Munich were leading authorities in the field. The hot keywords were nachizumab, leukodystrophy, leukoencephalopathy, subcortical infarction, disappeared white matter, etc., which could form 8 clusters. The journal with the highest frequency of citation was Neurology. The most frequency of citation was the paper published by Bloomgren G et al., on the risk of progressive multiform leukoencephalopathy associated with natazumab. The highest ranking central literature was an literature by Gorelik L et al. published in Ann Neurol in 2010 on the effect of anti-JC virus antibodies on risk stratification of leukoencephalopathy. Conclusion The application of CiteSpace in the literature analysis of clinical neuroscience of leukoencephalopathy in the past 15 years shows the current countries and institutions of cooperation，reveals the hot spots and directions of research，and has important reference value for the in-depth study of leukoencephalopathy.

Key words： Leukoencephalopathy Bibliometrics Visual analysis CiteSpace

基金资助:国家自然科学基金资助项目（81603443、815737 90）。

通讯作者: ▲通讯作者

引用本文:

韦妮娜徐曼曼潘菊华黄世敬▲ 王彦云. 基于CiteSpace脑白质病的相关文献分析[J]. 中国医药导报, 2020, 17(17): 9-14,20.
WEI Nina XU Manman PAN Juhua HUANG Shijing▲ WANG Yanyun. Analysis of related literature based on CiteSpace leukoencephalopathy. 中国医药导报, 2020, 17(17): 9-14,20.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2020/V17/I17/9

[1] 杨梦歌，郑超，刘玲玲，等.MRI上病灶呈双侧对称分布的脑白质病[J].中风与神经疾病杂志，2018，35（11）：1035-1041.
[2] 姚生.提高对不同类型遗传性脑小血管病的认识[J].中华老年心脑血管病杂志，2019，21（9）：897-900.
[3] 高亚军，屈永才.缺血性脑白质病的临床研究[J].延安大学学报：医学科学版，2018，16（2）：90-93.
[4] 韩露露，黄世敬.缺血性脑白质病的中医治疗进展[J].辽宁中医杂志，2019，46（4）：866-868.
[5] van der Knaap MS，Bugiani M，Mendes MI，et al. Biallelic variants in LARS2 and KARS cause deafness and（ovario）leukodystrophy [J]. Neurology，2019，92（11）：e1225-e1237.
[6] Gold R，Kappos L，Arnold DL，et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis [J]. N Engl J Med，2012，367（12）：1098-1107.
[7] Chabriat H，Hervé D，Duering M，et al. Predictors of clinical worsening in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy：prospective cohort study [J]. Stroke，2016，47（1）：4-11.
[8] Dichgans M. Dementia risk after transient ischaemic attack and stroke [J]. Lancet Neurol，2019，18（3）：223-225.
[9] Vanderver A，Simons C，Helman G，et al. Whole exome sequencing in patients with white matter abnormalities [J]. Ann Neurol，2016，79（6）：1031-1037.
[10] Polman CH，Reingold SC，Banwell B，et al. Diagnostic criteria for multiple sclerosis：2010 revisions to the McDonald criteria [J]. Annals of neurology，2011，69（2）：292-302.
[11] Kappos L，Bar-Or A，Cree BAC，et al. Siponimod versus placebo in secondary progressive multiple sclerosis（EXPAND）：a double-blind，randomised，phase 3 study [J]. Lancet，2018，391（10127）：1263-1273.
[12] Rudick RA，Cohen JA. Aspects of multiple sclerosis that relate to clinical trial design and treatment [M]. //Mult.Scler.Ther.CRC Press，2019：31-49.
[13] Van Assche G，Van Ranst M，Sciot R，et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn′s disease [J]. N Engl J Med，2005，353（4）：362-368.
[14] Kleinschmidt-DeMasters BK，Donson A，Foreman NK，et al. H3 K27M mutation in gangliogliomas can be associated with poor prognosis [J]. Brain Pathol，2017，27（6）：846-850.
[15] Hinchey J，Chaves C，Appignani B，et al. A reversible posterior leukoencephalopathy syndrome [J]. New Engl J Med，1996，334（8）：494-500.
[16] Berger JR. Classifying PML risk with disease modifying therapies [J]. Mult Scler Relat Disord，2017，12：59-63.
[17] Bloomgren G，Richman S，Hotermans C，et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy [J]. N Engl J Med，2012，366（20）：1870-1880.
[18] Gorelik L，Lerner M，Bixler S，et al. Anti-JC virus antibodies：implications for PML risk stratification [J]. Ann Neurol，2010，68（3）：295-303.
[19] Dowling E，Hamilton III GS，Janus J. Mayo Clinic，Roch-ester，MN，United States [J]. Handbook of Tissue Engineering Scaffolds：Volume One，2019：387.
[20] Westphalen CB，Preinfalk A，Kruger S，et al. Neurotrophic tropomyosin receptor kinase（NTRK）and nerve growth factor（NGF）are not expressed in Caucasian patients with biliary tract cancers：pooled data from three independent cohorts [J]. Clin Transl Oncol，2019，21（8）：1108-1111.